On September 24, 2020, the Supreme Court of Canada denied leave to Apotex (Docket No. 39172) with respect to a decision affirming the quantum of profits payable to the Plaintiffs ADIR and Servier for infringement of ADIR'S perindopril patent. As  previously reported, the Federal Court of Appeal found that the Federal Court made no palpable and overriding error in holding that Apotex would not have used a non-infringing alternative from third-party manufacturers. 

The preceding is intended as a timely update on Canadian intellectual property and technology law. The content is informational only and does not constitute legal or professional advice. To obtain such advice, please communicate with our offices directly.